ClinicalTrials.gg
RecruitingNCT07630987PLACARDUpdated Nov 6, 2026

Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.

An interventional study of Arterial blood sample and Arterial blood sample in Cardiac Surgery, Cardiopulmonary Bypass and Platelet Activation, sponsored by Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Université Catholique de Louvain · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The PLACARD research project aims to investigate the impact of CPB-induced platelet modifications during cardiac surgery on the post-operative inflammatory response and bleeding complications. Our objectives are to study the impact of CPB on the formation of procoagulant platelets, to assess changes in platelet lipid profile and bioenergetics before, during and after cardiac surgery, and to connect the ex-vivo observations to post-operative clinical and biological parameters of these patients during their stay in cardiovascular intensive care unit.

Read the detailed description

Cardiac surgery remains associated with high morbidity and mortality despite improvements in peri and post-operative care. Cardiopulmonary bypass (CPB) triggers a sterile inflammatory response, characterized by vascular hyperpermeability, excessive vasodilation, and cardiac arrythmias, i.e. atrial fibrillation. In parallel, major peri-operative bleeding frequently necessitates transfusion of allogeneic blood products. The pathophysiology underlying these complications is multifactorial. Direct contact of blood with the CPB tubing system, combined with ischemia-reperfusion injury, profoundly alters both the inflammatory and haemostatic systems. Among blood components, platelets are particularly vulnerable to CPB-induced alterations. Platelet dysfunction is widely recognized as the main haemostatic defect associated with CPB and a major contributor to post-operative bleeding. Recent findings have demonstrated that platelet lipid metabolism plays a key role in regulating thrombo-inflammatory responses in sepsis. These observations raise the hypothesis that CPB-induced alterations in platelet lipid metabolism may critically modulate the balance between inflammation and haemostasis in cardiac surgery.

The PLACARD project therefore aims to investigate how CPB-induced platelet modifications influence post-operative inflammatory responses and bleeding complications.

Specific objectives:

  1. Characterize the impact of CPB on the formation of procoagulant platelets.
  2. Assess changes in platelet lipid composition and bioenergetics before, during and after cardiac surgery.
  3. Correlate ex-vivo platelet alterations with post-operative clinical outcomes and biological markers during the stay in the cardiovascular intensive care unit.

This project addresses a critical unmet need in cardiac surgery: understanding the mechanistic link between CPB-induced platelet dysfunction and thrombo-inflammatory complications. By focusing on platelet lipid metabolism, a pathway largely unexplored in this context, the project moves beyond traditional platelet function assays. The results are expected to provide fundamental mechanistic insights into procoagulant platelet formation during CPB and may identify novel biomarkers or therapeutic targets to reduce bleeding and inflammatory complications in high-risk surgical patients.

02

Conditions studied

  • Cardiac Surgery
  • Cardiopulmonary Bypass
  • Platelet Activation

Keywords

  • Procoagulant platelets
  • Platelet lipidomics
  • Postoperative inflammation
  • Postoperative bleeding
03

In context

Postoperative Hemorrhage

135 studies on the registry are indexed under Postoperative Hemorrhage; 31 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 102 interventional studies indexed under Postoperative Hemorrhage.

Browse Postoperative Hemorrhage studies →

Lead sponsor

Université Catholique de Louvain is the lead sponsor of 155 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥ 18 years old) suffering from coronary disease and/or severe valvular dysfunction (mitral or aortic) undergoing elective coronary angiography or cardiac surgery with cardiopulmonary bypass.

Exclusion criteria

Exclusion Criteria:

  • Uninterrupted preoperative dual antiplatelet therapy
  • Active chronic inflammatory disease
  • Recent chemotherapy or immunotherapy (\< 3 months)
  • Active solid
  • History of hematologic malignancy
  • Hemophilia or other coagulopathy
  • History of thrombocytopenia (\< 100,000 /mm³)
  • Recent administration of thrombopoietin receptor agonist or immunoglobulins
  • History of thrombopathy, thrombocytosis, or myeloproliferative syndrome
  • History of heparin-induced thrombocytopenia (HIT)
  • Cirrhosis or hepatic fibrosis (with or without hypersplenism)
  • History of splenectomy, regardless of initial indication
  • History of systemic disease (e.g., systemic lupus erythematosus, scleroderma, antiphospholipid syndrome, systemic vasculitis)
  • Recent major surgery (\< 3 months)
  • Severe renal insufficiency ( ≤ 30 mL/min/m²) with or without dialysis
  • Recent or chronic therapy
  • Recent acute coronary syndrome, STEMI type (\< 3 months)
  • Urgent surgery or procedure
  • Preoperative hemodynamic instability
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cathlab patients

    This group includes patients with coronary disease and/or valvular disease scheduled for elective coronary angiography.

    Biological: Arterial blood sample

  • Experimental
    Cardiac surgery patients

    This arm includes patients with coronary disease and/or valvular disease scheduled for elective cardiac surgery with cardiopulmonary bypass.

    Biological: Arterial blood sample

Interventions

  • BiologicalArterial blood sample

    An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place, before administration of Heparin.

  • BiologicalArterial blood sample

    An arterial blood sample will be obtained via the arterial line before anesthetic induction, 60 minutes after the beginning of cardiopulmonary bypass and 4 hours after the arrival in the intensive care unit

06

What researchers measure

Primary outcomes

  1. Procoagulant platelet formation

    Ex-vivo flow cytometric assessment of the pourcentage of procoagulant platelet population under basal and stimulated conditions.

    Time frame: Throughout the entire study, approximately during 32 months

Secondary outcomes

  1. Platelet lipidomics

    Assessment of the impact of cardiac surgery and cardiopulmonary bypass on platelet lipid metabolism. Pourcentage of patients with platelet Acety-CoA Carboxylase phosphorylation.

    Time frame: Throughout the entire study, approximately during 32 months

  2. Postoperative bleeding

    Correlation between the ex-vivo primary outcomes and clinical postoperative parameters (chest drain output (mL) and need for blood transfusion (units of packed red cells, fresh frozen plasma, platelets and fibrinogen)).

    Time frame: Throughout the entire study, approximately during 32 months

  3. Postoperative inflammation

    Correlation between the ex-vivo primary outcomes and biological postoperative parameters (C-reactive protein).

    Time frame: Throughout the entire study, approximately during 32 months

  4. Postoperative platelet function

    Correlation between the ex-vivo primary outcomes and biological postoperative parameters (platelet aggregometry results).

    Time frame: Throughout the entire study, approximately during 32 months

  5. Postoperative coagulation

    Correlation between the ex-vivo primary outcomes and biological postoperative parameters (thromboelastography and standard coagulation results (INR, aPTT, Fibrinogen)).

    Time frame: Throughout the entire study, approximately during 32 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2029, 33 months after the start.

Of 35 non-industry interventional studies with no phase under Postoperative Hemorrhage, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 33 months is above that.

Counting every sponsor, half of 38 studies reached it within 14 months; a quarter within 8 and three quarters within 23.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Apr 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
Jun 5, 2026
StartActual
Apr 15, 2026was May 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
Cliniques universitaires Saint-Luc is now Recruiting
Nov 6, 2026
Start date
May 15, 2026→Apr 15, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    Cliniques universitaires Saint-Luc is now Recruiting
    Start date May 15, 2026→Apr 15, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07630987
Collaborators
Fonds National de la Recherche Scientifique, Fondation Mont-Godinne
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Apr 15, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Christophe Beauloye, MD, PhD
Contact
christophe.beauloye@uclouvain.be
003227642812
Richard Coulie, MD
Contact
richard.coulie@uclouvain.be

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion